Achieve Life Sciences Taps Esperion CFO to Lead Financial Strategy Ahead of Potential Cytisinicline Launch
Event summary
- Achieve Life Sciences appoints Benjamin Halladay as CFO effective October 5, 2026, replacing Mark Oki.
- Halladay previously led Esperion Therapeutics' finance team through its $1.1 billion sale to ARCHIMED.
- Achieve is preparing for potential commercialization of cytisinicline, a treatment for nicotine dependence.
- Cytisinicline has Breakthrough Therapy designation for vaping cessation and an NDA submission pending.
The big picture
Achieve's appointment of Halladay underscores its focus on financial strategy and operational efficiency as it approaches potential commercialization. Halladay's background in scaling commercial-stage pharma organizations and navigating high-value transactions positions Achieve to address a significant unmet need in nicotine dependence treatment. The move comes as the company seeks to capitalize on cytisinicline's Breakthrough Therapy designation and expand its market reach.
What we're watching
- Launch Readiness
- How Halladay's experience scaling commercial pharma organizations will impact Achieve's cytisinicline launch timeline and execution.
- Capital Efficiency
- Whether Achieve can maintain financial discipline while advancing cytisinicline through regulatory and commercial milestones.
- Regulatory Momentum
- The pace at which Achieve progresses its NDA resubmission and secures FDA approval for cytisinicline.
Related topics